BlueRock Therapeutics and bit.bio announce collaboration

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies

• Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs.
• Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio’s opti-ox™ precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies.
• bit.bio receives an upfront payment from BlueRock and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration. 

CAMBRIDGE, Massachusetts, 07:30 EDT and Cambridge, UK 12:30 BST, 3 August 2023: BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly-owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. 

“Tregs play a crucial role in maintaining balance in the body’s immune system and controlling excessive immune reactions. iPSC-derived Treg based therapies have the potential to treat a broad range of autoimmune and inflammatory disorders, and we look forward to collaborating with the bit.bio team to explore how their opti-ox cell programming technology can accelerate our efforts to discover and manufacture Tregs from iPSCs.”

 

 

      Stefan Irion
      MD, Chief Scientific Officer of BlueRock Therapeutics

 

Under the terms of the agreement, bit.bio will use its machine learning powered discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. The agreement also includes options for BlueRock to license bit.bio’s opti-ox precision cell programming technology to control the expression of TF combinations within Treg cell therapies. opti-ox uses a dual genomic safe harbour approach to cell programming, and bit.bio uses opti-ox to drive the rapid TF-mediated conversion of iPSCs into highly defined cell types in a single step. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency.

"We are delighted to partner with the team at BlueRock, who are world-leaders in iPSC-derived cell therapies, and together address the significant unmet needs of these patients. Today’s announcement marks an important milestone for bit.bio. As well as providing significant financial contributions, our collaboration is a testament to the unique capabilities of bit.bio's team.”

 

 

      Mark Kotter
      bit.bio founder and CEO

 

BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from the collaboration. bit.bio receives an upfront payment and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration.

Notes to Editors

About BlueRock Therapeutics LP 
BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for patients suffering from neurological, cardiovascular, immunological, and ophthalmic diseases. Our lead clinical program, bemdaneprocel, (BRT-DA01) is in Phase I clinical trials for Parkinson’s disease. We were founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed Cell & Gene Therapy Platform. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. For more information, visit www.bluerocktx.com  

About Bayer 
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.